Adherence and effectiveness of the treatment of latent tuberculosis infection with isoniazid for 9 months in a cohort of 755 patients;Cumplimiento y efectividad del tratamiento de la infección tuberculosa con isoniazida durante 9 meses en una cohorte de 755 pacientes

Medicina Clinica

Volumn 130, Issue 5, 2008, Pages 165-171

  Pina Gutiérrez, José María ^a,b,c   Ferrer Traid, Anna ^b   Arias, César ^b   Sala Farré, María Rosa ^b   López Sanmartín, José L ^b  

^a INSTITUT CATALÀ DE LA SALUT   (Spain)

^b GENERALITAT DE CATALUNYA   (Spain)

^c NONE   (Spain)

Author keywords

Adherence; Effectiveness; Treatment of latent tuberculosis infection

Indexed keywords

ISONIAZID;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; LIVER TOXICITY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PATIENT CODING; PATIENT COMPLIANCE; TREATMENT DURATION;

EID: 41949102404     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1157/13116320     Document Type: Article

References (29)

1. Rieder HL. Preventive chemotherapy. En: Rieder HL. Interventions for tuberculosis control and elimination. Paris: International Union Against Tuberculosis and Lung Disease; 2002. p. 127-46.
2. Srterling TR, Bethel J, Goldberg S, Weinfurter P, Yun L, Horsburgh, et al. Tuberculosis Epidemiologic Studium Consortium. The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med. 2006;173:927-31.
3. Broekmans JF, Migliori GB, Rieder HL, Lees J, Ruutu P, Loddenkemper R, et al. European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the WHO, IUATLD and KNVC Working Group. Eur Respir J. 2002;19:765-75U.
4. ATS/CDC Statement Committee on Latent Tuberculosis Infection. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2000;49:1-51.
5. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bulletin Wordl Health Org. 1982;60:555-64.
6. Comstock GW. How much isoniazid is need for prevention of tuberculosis among inmunocompetent adults? Int J Tuberc Lung Dis. 1999;3:847-50.
7. Reichman LB, Lardizabal A, Hayden CH. Considering the role of four months of rifampin in the treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2004;170:832-5.
8. Menzies D, Dion MJ, Rabinovitch, Mannix S, Brassard P, Scgwartzman K. Tratment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med. 2004;170:445-9.
9. Page KR, Sifakis F, Montes de Oca R, Cronin WA, Doherty MC, Federline L, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis. Arch Intern Med. 2006;166:1863-70.
10. Lee CH, Lee CJ. Thombocytopenia: a rare but potencially serious side effect of initial daily and interrupted use of rifampin. Chest. 1989;96:202-3.
11. American Thoracic Society Documents. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174:935-52.
12. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. Chest. 1991;99:465-71.
13. CDC. Update: adverse event data and revised American Thoracic Society/CDC. Recommendations against the use of rifampin and pyrazinamid for treatment of latent tuberculosis infection - United States, 2003. MMWR Morb Mortal Wkly Rep. 2003;52:735-9.
14. Ferebee SH. Controlled chemoprophylaxis trials in tu berculosis: a general review. Bibl Tuberc. 1970;26:28-106.
15. Pina JM, Sala MR, López JL, Miret P. Programa de la Tuberculosi, actualització 2000. Terrassa: Servei Català de la Salut Regió Sanitaria Centre. Institut Català de la Salut Divisió d'Atenció Primària; 2000. p. 43-52.
16. WHO. Collaborating Center for Drug International Monitoring. ART: adverse drug reaction terminology. Geneva: WHO; 1979.
17. Vynnycky E, Fine PE. The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiol Infect. 1997;119:183-201.
18. Grzybowski S, Enarson D. Tuberculosis. En: Simmons DH, editor. Current pulmonogy. Chicago, London: Year Book Medical; 1986. p. 73-96.
19. Martínez E, Solera J, Serna, Cuenca D, Castillejos ML, Espinosa A, et al. Cumplimentación, tolerancia y eficacia de una pauta corta de quimioprofilaxis para el tratamiento de la tuberculosis. Med Clin (Barc). 1998;111:401-4.
20. Cook PP, Maldonado RA, Yarnell CT, Holbert D. Safety and completion rate of short-course therapy for treatment of latent tuberculosis. Clin Infect Dis. 2006;43:271-5.
21. Shieh FK, Snyder G, Horsburg CR, Bernardo J, Murphy C, Saukkonen JJ. Predicting non-completion of treatment for latent tuberculosis infection. A prospective survey. Am J Respir Crit Care Med. 2006;174:717-21.
22. Styblo K. Epidemiology of tuberculosis. Selected papers. The Hage: Royal Netherlands Tuberculosis Association; 1991. p. 55-67.
23. Sutherland I, Svandová E, Radhakrishna SE. The development of clinical tuberculosis following infection with tubercle bacilli. 1: a theoretic model for the development of clinical tuberculosis following infection, linking from data on thr risk of tuberculosis infection and the incidence of clinical tuberculosis in the Netherlands. Tubercle. 1982;63:255-68.
24. Comstock GW, Baum C, Snider DE Jr. Isoniazid prophylaxis among Alaskan Eakimos: a final report of the Bethel Isoniazid Studies. Am Rev Respir Dis. 1979;119:827-30.
25. Fletcher RH, Fletcher SW, Wagner EH. Tratamiento. En: Fletcher RH, Fletcher SW, Wagner EH, editores. Epidemiología clínica. Barcelona: Consulta; 1989. p. 129-55.
26. Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazida para la prevención de tuberculosis en las personas no infectadas por VIH [Revisión Cochrane traducida]. En: La Biblioteca Cochrane Plus; 2005, número 4. Oxford: Update Software Ltd. Disponible en: http//www.update-software.com
27. Galván F, Santiuste C. Factores relacionados con el cumplimiento de la quimioprofilaxis contra la tuberculosis. Med Clin (Barc). 1998;111: 655-7.
28. Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghof E, et al. Short-course rifampin and pyrazinamide compared with isoniazid for laten tuberculosis infection: a multicenter clinical trial. Ann Intern Med. 2002; 137:640-7.
29. Reicheler MR, Reves R, Bur S, Ford J, Thompson V, Mangura B, et al. Treatment of latent tuberculosis infection in contacts of new tuberculosis cases in the United States. South Med J. 2002;95:414-20.